Sinorda Pharmaceutical Receives National Recognition as a High-Tech Enterprise

On December 25, 2024, the Office of the National Leading Group for the Management of High-Tech Enterprise Recognition released the "Public Notice on Filing the Second Batch of High-Tech Enterprises Recognized and Filed by Guizhou Province in 2024," announcing that Sinorda Pharmaceutical has been granted the designation of "National High-Tech Enterprise."

A high-tech enterprise is one that continuously engages in research and development as well as the commercialization of technological innovations within the "National Key Areas of High-Tech Support," thereby establishing core, independently owned intellectual property rights that form the foundation for its business operations. Such enterprises are overseen by the National Leading Group for the Identification and Management of High-Tech Enterprises, jointly established by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation, and enjoy unparalleled authority and widespread recognition.

Sinorda Pharma is dedicated to the development of innovative drugs for gastrointestinal diseases and tumor immunotherapy, boasting comprehensive biopharmaceutical R&D capabilities, an experienced technical and management team, and extensive collaborative expertise in drug innovation and international partnerships across China, the U.S., and Europe—ensuring rapid project initiation and advancement. The recognition as a "National High-Tech Enterprise" is a well-deserved acknowledgment of Sinorda Pharma's past efforts. Moving forward, we remain committed to our original vision, continuing to pursue excellence and light on the path of research and innovation.